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Fractional ﬂ ow reserve versus angiography for guidance of 
PCI in patients with multivessel coronary artery disease 
(FAME): 5-year follow-up of a randomised controlled trial
Lokien X van Nunen*, Frederik M Zimmermann*, Pim A L Tonino, Emanuele Barbato, Andreas Baumbach, Thomas Engstrøm, Volker Klauss, 
Philip A MacCarthy, Ganesh Manoharan, Keith G Oldroyd, Peter N Ver Lee, Marcel van’t Veer, William F Fearon, Bernard De Bruyne, Nico H J Pijls, 
for the FAME Study Investigators
Summary
Background In the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) study, fractional 
ﬂ ow reserve (FFR)-guided percutaneous coronary intervention (PCI) improved outcome compared with angiography-
guided PCI for up to 2 years of follow-up. The aim in this study was to investigate whether the favourable clinical 
outcome with the FFR-guided PCI in the FAME study persisted over a 5-year follow-up.
Methods The FAME study was a multicentre trial done in Belgium, Denmark, Germany, the Netherlands, Sweden, 
the UK, and the USA. Patients (aged ≥18 years) with multivessel coronary artery disease were randomly assigned to 
undergo angiography-guided PCI or FFR-guided PCI. Before randomisation, stenoses requiring PCI were identiﬁ ed 
on the angiogram. Patients allocated to angiography-guided PCI had revascularisation of all identiﬁ ed stenoses. 
Patients allocated to FFR-guided PCI had FFR measurements of all stenotic arteries and PCI was done only if FFR 
was 0·80 or less. No one was masked to treatment assignment. The primary endpoint was major adverse cardiac 
events at 1 year, and the data for the 5-year follow-up are reported here. Analysis was by intention to treat. This trial is 
registered with ClinicalTrials.gov, number NCT00267774.
Findings After 5 years, major adverse cardiac events occurred in 31% of patients (154 of 496) in the angiography-
guided group versus 28% (143 of 509 patients) in the FFR-guided group (relative risk 0·91, 95% CI 0·75–1·10; 
p=0·31). The number of stents placed per patient was signiﬁ cantly higher in the angiography-guided group than in 
the FFR-guided group (mean 2·7 [SD 1·2] vs 1·9 [1·3], p<0·0001).
Interpretation The results conﬁ rm the long-term safety of FFR-guided PCI in patients with multivessel disease. A 
strategy of FFR-guided PCI resulted in a signiﬁ cant decrease of major adverse cardiac events for up to 2 years after the 
index procedure. From 2 years to 5 years, the risks for both groups developed similarly. This clinical outcome in the 
FFR-guided group was achieved with a lower number of stented arteries and less resource use. These results indicate 
that FFR guidance of multivessel PCI should be the standard of care in most patients.
Funding St Jude Medical, Friends of the Heart Foundation, and Medtronic.
Introduction
In addition to coronary angiographic abnormalities, the 
presence and extent of inducible myocardial ischaemia is 
an important prognostic factor in coronary artery 
disease.1–3 The absence of inducible myocardial ischaemia 
is associated with excellent outcome during medical 
treatment.1,4 Therefore, revascularisation of non-
ischaemic stenoses is usually not indicated. How ever, 
revascularisation of ischaemia-inducing stenoses 
improves symptoms and outcome.5,6
Fractional ﬂ ow reserve (FFR) is deﬁ ned as the ratio of 
maximum blood ﬂ ow in a stenotic coronary artery to 
maximum blood ﬂ ow if the same artery were completely 
normal. An FFR of 0·80 or less, as measured with the 
use of a coronary pressure wire during invasive coronary 
angiography, indicates the potential of a speciﬁ c stenosis 
to induce myocardial ischaemia with an accuracy of 
greater than 90%. Therefore, FFR is recommended for 
the guidance of coronary revascularisation.7,8
In the Fractional Flow Reserve Versus Angiography 
for Multivessel Evaluation (FAME) study,9 we compared 
angiography-guided percutaneous coronary inter-
vention (PCI) with FFR-guided PCI in multivessel 
disease. At 1 year, the proportion of major adverse 
cardiac events was signiﬁ cantly lower and a higher 
proportion of patients were free from angina in the 
FFR-guided group than in the angiography-guided PCI 
group.9 At 2 years, the rates of death and myocardial 
infarction were signiﬁ cantly lower in the FFR-guided 
group.10 Additionally, use of FFR-guided PCI was 
cost-saving.11 The results of the FAME study 
contributed to a shift from purely anatomical to func-
tional revascular isation strategies. However, the long-
term safety of such a strategy has not been studied 
so far.
The goal in this analysis was to investigate whether the 
favourable outcome with the FFR-guided PCI in the 
FAME study persisted over 5 years of follow-up.
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Methods
Study design and participants
The design of the FAME study has been described 
previously.12 Brieﬂ y, FAME was a multicentre, randomised 
controlled trial, done in the USA and six European 
countries (Belgium, Denmark, Germany, the Netherlands, 
Sweden, and the UK).
The institutional review board of each participating 
centre provided ethics approval. All patients provided 
written informed consent.
Patients (aged ≥18 years) were included in the study if 
they had coronary artery stenoses of at least 50% of the 
vessel diameter in at least two major epicardial coronary 
arteries, and if clinical data and angiographic appearance 
indicated PCI. Exclusion criteria were angiographically 
signiﬁ cant left main coronary artery disease, previous 
coronary artery bypass surgery, cardiogenic shock, 
extremely tortuous or calciﬁ ed coronary arteries, a life 
expectancy of less than 2 years, pregnancy, and 
contraindication to the placement of a drug-eluting 
stent. Recent myocardial infarction was not an exclusion 
criterion if it occurred at least 5 days before PCI. 
With respect to non-ST-elevation myocardial infarction, 
patients could be included earlier than 5 days before PCI 
if the peak creatine kinase concentration was less than 
1000 IU.
Randomisation and masking
Patients with multivessel coronary artery disease were 
randomly assigned with a computer-generated allocation 
sequence to have angiography-guided PCI or FFR-guided 
PCI. Randomisation was stratiﬁ ed according to the study 
site and done in blocks of 25, with the use of sealed opaque 
envelopes. Patients allocated to angiography-guided PCI 
underwent revascularisation of all angiographic stenoses 
with drug-eluting stents. Patients allocated to FFR-guided 
PCI had FFR measurement of all stenotic arteries and PCI 
was done only if FFR was 0·80 or less. No one was masked 
to treatment assignment.
Treatment
PCI was done with drug-eluting stents. In the 
angiography-guided group, all indicated angiographically 
signiﬁ cant stenoses were stented. In the FFR-guided 
group, a coronary pressure wire (Radi, St Jude Medical, 
Uppsala, Sweden) was advanced and equalised with the 
pressure sensor at the tip of the guiding catheter. 
Hereafter, the pressure wire was advanced in the 
coronary artery, suﬃ  ciently distal to the lesion under 
investigation. Maximum coronary hyperaemia was 
induced with central venous infusion of adenosine 
(140 μg/kg per min) and FFR was measured. If FFR was 
less or equal to the ischaemic threshold (ie, 0·80), PCI of 
the respective stenosis was done. All patients were 
treated with aspirin and clopidogrel for at least 1 year.
Outcomes
The primary endpoint in the FAME study was the rate of 
major adverse cardiac events at 1 year; the 5-year follow-up 
data are reported here. The deﬁ nition of major adverse 
cardiac events was a composite of death, myocardial 
infarction, and any repeat revascularisation. In the FAME 
study, death was deﬁ ned as all-cause mortality.
Predeﬁ ned secondary endpoints were major adverse 
cardiac events at 2 years and 5 years, and the individual 
components of the major adverse cardiac events at 1 year, 
Research in context
Evidence before this study
Fractional ﬂ ow reserve (FFR) indicates the potential of a 
speciﬁ c stenosis to induce myocardial ischaemia with an 
accuracy of more than 90%. Therefore, FFR is recommended 
for the guidance of coronary revascularisation, as described by 
the guidelines of the European Society of Cardiology and 
American Heart Association–American College of Cardiology. 
In the Fractional Flow Reserve Versus Angiography for 
Multivessel Evaluation (FAME) study, angiography-guided 
percutaneous coronary intervention (PCI) was compared with 
FFR-guided PCI in multivessel disease. At 1 year, the rate of 
major adverse cardiac events was signiﬁ cantly lower in the 
FFR-guided group and equally high percentages of patients 
were free from angina in both groups. At 2 years, an ongoing 
favourable outcome was noted with signiﬁ cantly lower rates 
of death and myocardial infarction in the FFR-guided group 
than in the angiography-guided PCI group. Additionally, FFR-
guided PCI was cost-saving.
Added value of this study
The current analysis shows that for up to 5 years, the absolute 
diﬀ erence in events persist, but is not signiﬁ cant because of the 
smaller number of patients at risk and the similar incidence of 
events in both groups beyond 2 years. These results indicate 
that the beneﬁ t of FFR-guided PCI occurs mainly during the ﬁ rst 
2 years and thereafter the risks in both groups develop similarly. 
Moreover, the results conﬁ rm the long-term safety of 
FFR-guided PCI in patients with multivessel disease.
Implications of all the available evidence
This new evidence of long-term safety of FFR-guided PCI in 
patients with multivessel disease will further strengthen the 
evidence of beneﬁ t of functional revascularisation over 
anatomical revascularisation. This is the ﬁ rst study of the 
long-term results of FFR-guided strategy and the results show 
that, with optimum medical therapy, revascularisation of only 
functional signiﬁ cant lesions is safe and will not result in a late 
catch-up phenomenon because of the progression of 
atherosclerosis in non-signiﬁ cant lesions. 
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2 years, and 5 years;12 data for the major adverse cardiac 
events and the individual components at 5 years are 
reported here. Although major adverse cardiac events for 
up to 2 years were adjudicated by a clinical event 
committee, events thereafter were assessed at the site and 
veriﬁ ed by source documentation (cardiac enzymes, 
electrocardiogram [ECG] changes, PCI reports, and cause 
of death).
For the 5-year follow-up, cardiac death was also assessed; 
this was not a prespeciﬁ ed endpoint. Death from an 
unknown cause was designated as cardiac death.
Statistical analysis
Primary and secondary endpoints were assessed with the 
intention-to-treat analysis. For these endpoints, we used 
the χ² test to compare the two groups. Endpoints 
throughout the 5-year follow-up were visualised with the 
use of Kaplan-Meier curves, using the log-rank test to 
compare the two groups.
Data were presented as mean (SD). Discrete variables 
were compared by use of the χ² test or Fisher’s exact test 
as appropriate, whereas continuous variables were 
compared by use of the Student’s t test or Mann-Whitney 
U test as appropriate. Patients lost to follow-up were 
censored at the date of last contact. A sensitivity analysis, 
assuming all patients lost to follow-up died at the last 
follow-up, was done to investigate potential eﬀ ects of 
under-reporting due to loss to follow-up. To adjust for 
potential confounders, we did a multivariate logistic 
regression analysis using the following variables: sex, 
age, presence of diabetes, unstable angina or non-ST-
elevation myocardial infarction, ejection fraction of less 
than 40%, SYNTAX score,13 presence of proximal left 
anterior descending (LAD) involvement, and inclusion 
site.
Post-hoc subgroup analyses were done, with 
subgroups deﬁ ned according to sex, age, presence or 
absence of diabetes, stable angina versus unstable 
angina or non-ST-elevation myocardial infarction, 
ejection fraction of at least 40% or less than 40%, 
SYNTAX score of 22 or less, 23–32, or 33 or greater, and 
the presence or absence of proximal LAD involvement. 
Relative risks (RR) were calculated with 95% CIs and 
p values for interaction.
All statistical tests were two-tailed and a p value of less 
than 0·05 was signiﬁ cant. The acquired data were 
analysed with IBM SPSS for Windows (version 19.0.0.1). 
This trial is registered with ClinicalTrials.gov, number 
NCT00267774.
Role of the funding source
The funders of the study had no role in data gathering, 
analysis, and interpretation, writing of the manuscript, 
and the decision to submit for publication. The 
corresponding author had full access to all the data in the 
study and had ﬁ nal responsibility for the decision to 
submit for publication.
Results
1005 patients were included in 20 centres in the USA 
and Europe between Jan 2, 2006, and Sept 26, 2007 
(ﬁ gure 1). 496 patients were randomly assigned to 
angiography-guided PCI and 509 patients were assigned 
to FFR-guided PCI. Baseline characteristics, the number 
of indicated lesions, and the severity of coronary artery 
disease were similar between the two groups (appendix). 
Mean age of the study population was 64 years (SD 10), 
and about 75% were men (appendix). Most of the 
patients had more than one risk factor for coronary 
artery disease (appendix). The incidence of diabetes was 
not diﬀ erent between the two groups (appendix). 37% of 
the patients had previous myocardial infarction and 
27% had previous PCI (appendix). The severity of 
coronary artery disease was well balanced between the 
two groups, with a similar number of lesions per patient 
and a similar percentage of patients with a proximal 
LAD stenosis (appendix).
The procedure times did not diﬀ er between the 
angiography-guided group and the FFR-guided group 
(mean 70 min [SD 44] vs 71 min [43]; p=0·51). In the 
FFR-guided group, FFR measurement was done in 
1329 (94%) of 1414 indicated lesions. FFR measurement 
Figure 1: Trial proﬁ le
PCI=percutaneous coronary intervention.
1905 patients assessed for eligibility
900 not eligible
 157 left main artery stenosis
 217 extreme vessel tortuosity or calciﬁcation 
 105 did not provide consent
 86 contraindication for drug-eluting stent
 94 participating in another study
 210 logistical reasons
 31 other reasons
1005 randomly assigned
496 angiography-guided PCI
11 lost to follow-up 8 lost to follow-up
485 1-year follow-up
25 lost to follow-up 21 lost to follow-up
460 2-year follow-up
31 lost to follow-up 44 lost to follow-up
429 complete 5-year follow-up
509 fractional ﬂow reserve-guided PCI
501 1-year follow-up
480 2-year follow-up
436 complete 5-year follow-up
See Online for appendix
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was not successful in 27 stenoses, and was not done in 
58 stenoses with a chronic total occlusion for which a 
default value of 0·50 was assigned in accordance with the 
protocol. In 874 (63%) of 1387 stenoses, FFR was 0·80 or 
less, and these stenoses were treated with PCI as per 
protocol.
In the complete study population, 2415 stents were 
placed, of which 2339 (97%) were drug-eluting stents. In 
the angiography-guided group, the number of stents 
placed per patient was signiﬁ cantly higher than in the 
FFR-guided group (mean 2·7 [SD 1·2] vs 1·9 [1·3], 
p<0·0001).
865 (86%) of 1005 patients had complete 5-year 
follow-up. 67 patients in the angiography-guided group 
and 73 in the FFR-guided group were lost to follow-up 
(p=0·70). The characteristics of the patients who 
completed the 5-year follow-up are shown in table 1, 
and did not diﬀ er from baseline characteristics of the 
total patient population at the start of the study 
(appendix).
After 5 years, the primary endpoint (major adverse 
cardiac events) occurred in 31% of patients (154 of 496) 
in the angiography-guided group versus 28% (143 of 
509 patients) in the FFR-guided group (RR 0·91, 
95% CI 0·75–1·10; p=0·31). Sensitivity analysis showed 
no diﬀ erence in major adverse cardiac events if all 
patients lost to follow-up had died (appendix). Figure 2 
shows event-free survival. Potential confounders did 
not alter the eﬀ ect of treatment strategy on event-free 
survival with multivariate logistic regression (data not 
shown).
All-cause mortality at 5 years was 10% (49 of 496 patients) 
in the angiography-guided group, and 9% (44 of 509 
patients) in the FFR-guided group (RR 0·88, 95% CI 
0·59–1·29; p=0·50). Myocardial infarction occurred in 
12% of patients (n=58) in the angiography-guided group 
and 9% (n=48) in the FFR-guided group at 5 years 
(RR 0·81, 95% CI 0·56–1·16; p=0·24). Three patients 
(two in the angiography-guided group and one in the 
FFR-guided group) had a second acute myocardial 
infarction during follow-up, bringing the total number of 
myocardial infarctions to 60 versus 49. At 5 years, 20% of 
patients (n=98) in the angiography-guided group and 17% 
(n=86) in the FFR-guided group died or had myocardial 
infarction (RR 0·86, 95% CI 0·66–1·11; p=0·24). In the 
angiography-guided group, 17% of patients (n=82) 
required repeat revascularisation versus 15% (n=76) in 
the FFR-guided group (RR 0·90, 95% CI 0·68–1·20; 
p=0·49). 26 patients (12 in the angiography-guided group 
and 14 in the FFR-guided group) needed two or more 
revascularisation procedures. The total number of repeat 
revascularisations was 101 in the angiography-guided 
group and 92 in the FFR-guided group.
The absolute diﬀ erence in all-cause mortality between 
the two groups after 1 year, 2 years, and 5 years remained 
constant (1·2%, 1·2%, and 1·3%; table 2). The diﬀ erence 
in mortality at 5 years was exclusively due to cardiac 
mortality, which was 6% (28 of 496 patients) in the 
angiography-guided group versus 4% (21 of 509 patients) 
in the FFR-guided group (RR 0·73, 95% CI 0·42–1·27; 
p=0·26). Also, the diﬀ erences in mean number of events 
per patient between angiography-guided and FFR-guided 
strategies remained constant after 1 year, 2 years, and 
5 years (0·08, 0·08, and 0·06; table 2).
In the subgroup analyses, the interaction between sex 
and treatment strategy was signiﬁ cant, with FFR-
Angiography-guided 
PCI (n=429)
Fractional ﬂ ow reserve-
guided PCI (n=436)
p value
Baseline characteristics
Age (years) 63·9 (10·0) 64·5 (10·4) 0·41
Men/women 318 (74%)/111 (26%) 328 (75%)/108 (25%) 0·71
Clinical characteristics
Angina (Canadian Cardiovascular Society class) 0·32
I 97 (23%) 111 (25%)
II 142 (33%) 143 (33%)
III 105 (24%) 115 (26%)
IV 85 (20%) 67 (15%)
Diabetes 107 (25%) 98 (22%) 0·36
Hypertension 277 (65%) 259 (59%) 0·09
Hypercholesterolaemia 316 (74%) 307 (70%) 0·26
Family history of ischaemic heart disease 169 (39%) 178 (41%) 0·69
Current smoker 130 (30%) 111 (25%) 0·11
Previous myocardial infarction 155 (36%) 154 (35%) 0·86
Previous PCI 110 (26%) 123 (28%) 0·39
Unstable angina
With ECG changes 81 (19%) 61 (14%) 0·05
Without ECG changes 74 (17%) 67 (15%) 0·44
Left ventricular ejection fraction 57% (12) 57% (11) 0·75
Medication
β blocker 321 (75%) 334 (77%) 0·54
Calcium antagonist 86 (20%) 100 (23%) 0·30
Nitrates 156 (36%) 137 (31%) 0·13
Angiotensin-converting-enzyme inhibitor or 
angiotensin-receptor blocker
213 (50%) 225 (52%) 0·57
Statin 341 (79%) 358 (82%) 0·33
Aspirin 390 (91%) 396 (91%) 0·97
Clopidogrel 243 (57%) 256 (59%) 0·54
Angiographic characteristics
Indicated lesions per patient 2·7 (0·9) 2·8 (1·0) 0·37
Extent of occlusion* 1171 1221
50–70% narrowing 508 (43%) 549 (45%)
70–90% narrowing 468 (40%) 453 (37%)
90–99% narrowing 165 (14%) 171 (14%)
Total occlusion 30 (3%) 48 (4%)
Patients with proximal left anterior 
descending artery lesion
160 (37%) 178 (41%) 0·29
Patients with total occlusion 28 (7%) 45 (10%) 0·05
Data are mean (SD) or number (%). PCI=percutaneous coronary intervention. ECG=electrocardiogram. *The 
investigator indicated all lesions to be included in the study before randomisation and classiﬁ ed them according to 
severity by visual estimation. 
Table 1: Baseline and angiographic characteristics of patients with complete 5-year follow-up
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guided PCI favouring the male sex (pinteraction=0·027; 
ﬁ gure 3).
With focus solely on the male sex, the primary endpoint 
at 5 years occurred in 34% of patients (121 of 360) in the 
angiography-guided group versus 27% (103 of 384) in the 
FFR-guided group (RR 0·80, 95% CI 0·64–0·99; p=0·044).
In the angiography-guided group, the mean number of 
events per patient was 0·42 (SD 0·76) versus 0·36 (0·67) 
in the FFR-guided group during the 5-year follow-up 
(p=0·28; table 3). The cumulative events per 100 patient-
years during follow-up were higher in the angiography-
guided group (appendix).
Discussion
The current analysis shows that up to 5 years, the 
absolute diﬀ erence in cardiac events persists, but is not 
signiﬁ cant because of the smaller number of patients at 
risk and the similar incidence of events in both groups 
beyond 2 years. These results indicate that the beneﬁ t of 
FFR-guided PCI occurs mainly during the ﬁ rst 2 years, 
thereafter the risks increase similarly in both groups. 
Moreover, the results conﬁ rm the long-term safety of 
FFR-guided PCI in patients with multivessel disease.10
Routine measurement of FFR allows more judicious use 
of stents than does angiography and equal relief of 
Figure 2: Kaplan-Meier curves for survival free from major adverse cardiac events (A), all-cause mortality (B), all-cause mortality or myocardial infarction (C), 
and revascularisation (D)
FFR=fractional ﬂ ow reserve. PCI=percutaneous coronary intervention.
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ischaemia. Thus, by systematic measurement of FFR, the 
beneﬁ t of PCI can be maximised by accurate discrimination 
of the stenoses that beneﬁ t most from revascularisation.
The potential beneﬁ t of revascularisation depends on 
the extent and degree of myocardial ischaemia.1,14,15 In 
patients with multivessel disease, non-invasive testing 
often has too low spatial resolution to identify ischaemia 
associated with individual stenoses.16 When based solely 
on anatomical criteria, attempts to achieve complete 
revascularisation have led to the use of a high number of 
stents associated with a high rate of major adverse 
cardiac events.13 The notion of functional complete 
revascularisation rather than anatomical complete 
revascularisation overcomes these limitations by 
complete relief of ischaemia related to the epicardial 
vessel with better outcome and less resource use.10,17,18 An 
FFR value of 0·80 or less indicates the potential of a 
particular coronary stenosis to induce myocardial 
ischaemia with an unsurpassed spatial resolution.
With respect to all-cause mortality and cardiac 
mortality, there were no signiﬁ cant diﬀ erences between 
the two groups. There was reduction in the RR of 12% in 
the FFR-guided group for all-cause mortality, whereas 
the RR reduction for cardiac mortality was 27%. In a 
study with such a long follow-up, mortality numbers 
related to the speciﬁ c disease studied are diluted by 
naturally occurring other causes of death. Therefore, we 
believe that cardiac mortality in itself is a relevant factor 
when studying long-term follow-up. Although not 
signiﬁ cant, the absolute reduction in mortality was 
constant over time, as was the reduction in mean 
number of events per patient. As shown in table 2, the 
diﬀ erence in mortality at 5 years is solely due to the 
diﬀ erence in cardiac mortality.
Angiography-
guided PCI 
(n=496)
Fractional 
ﬂ ow reserve-
guided PCI 
(n=509)
Absolute 
diﬀ erence*
All-cause mortality
1-year follow-up 3·0% 1·8% 1·2%
2-year follow-up 3·8% 2·6% 1·2%
5-year follow-up 9·9% 8·6% 1·3%
Cardiac mortality
1-year follow-up 2·0% 1·4% 0·6%
2-year follow-up 2·4% 1·8% 0·6%
5-year follow-up 5·6% 4·1% 1·5%
Number of events per patient
1-year follow-up 0·23 (0·53) 0·15 (0·41) 0·08
2-year follow-up 0·29 (0·60) 0·21 (0·48) 0·08
5-year follow-up 0·41 (0·76) 0·35 (0·67) 0·06
Data are number (%) or mean (SD). PCI=percutaneous coronary intervention. 
*None of the diﬀ erences were signiﬁ cant. 
Table 2: Event rates during follow-up
Angiography-
guided PCI 
(n=496)
Fractional ﬂ ow 
reserve-guided 
PCI (n=509)
p value
Total events 210 185
Events per patient 0·42 (0·76) 0·36 (0·67) 0·28
Endpoints
All-cause mortality 49 (10%) 44 (9%) 0·50
Cardiac mortality 28 (6%) 21 (4%) 0·26
Myocardial infarction 60 49
Revascularisation 101 92
Combined endpoints
Major adverse cardiac 
events (primary 
endpoint)
154 (31%) 143 (28%) 0·31
All-cause mortality or 
myocardial infarction
98 (20%) 86 (17%) 0·24
Cardiac mortality or 
myocardial infarction
78 (16%) 66 (13%) 0·21
Data are number, mean (SD), or number (%). PCI=percutaneous coronary 
intervention.
Table 3: Outcomes at 5-year follow-up
Figure 3: Subgroup analyses of the primary endpoint major cardiac adverse events at 5 years
Data are n/N (%), unless otherwise indicated. Relative risks (with 95% CI) of the primary endpoint are shown by 
subgroup. FFR=fractional ﬂ ow reserve. PCI=percutaneous coronary intervention.
Relative risk (95% CI) pinteraction
Sex
 Male
 Female
Age (years)
 ≤70
 >70
Diabetes
 No
 Yes
Presentation
 Stable angina pectoris
 Unstable angina pectoris
 or non-ST-elevation
 myocardial infarction
Ejection fraction
 ≥40%
 <40%
SYNTAX score
 ≤22
 23–32
 ≥33
Left anterior descending or left
main artery involvement
 No
 Yes
Total
0·027
0·43
0·74
0·97
0·13
0·30
0·59
Number
744
261
707
295
753
248
677
328
858
57
813
80
44
722
283
1005
Angiography-
guided PCI
 121/360 (34%)
 33/136 (24%) 
 98/351 (28%)
 56/142 (39%)
 104/367 (28%)
 48/125 (38%)
 97/318 (31%)
 57/178 (32%)
 123/425 (29%)
 14/32 (44%)
 124/407 (30%)
 13/41 (32%)
 9/20 (45%)
 111/364 (30%)
 43/132 (33%)
 154/496 (31%)
FFR-
guided PCI
 103/384 (27%)
 40/125 (32%)
 93/356 (26%)
 50/153 (33%)
 97/386 (25%)
 46/123 (37%)
 99/359 (28%)
 44/50 (29%)
 116/433 (27%)
 14/25 (56%)
 115/406 (28%)
 11/39 (28%)
 5/24 (21%)
 102/358 (28%)
 41/151 (27%)
 143/509 (28%)
0·80 (0·64–0·99)
1·32 (0·89–1·95)
0·94 (0·73–1·19)
0·83 (0·61–1·13)
0·89 (0·70–1·12)
0·97 (0·71–1·34)
0·90 (0·71–1·15)
0·92 (0·66–1·27)
0·93 (0·75–1·15)
1·28 (0·76–2·16)
0·93 (0·75–1·15)
0·89 (0·45–1·74)
0·46 (0·10–1·16)
0·83 (0·58–1·19)
0·93 (0·75–1·17)
0·91 (0·75–1·10)
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The beneﬁ t of FFR-guided PCI achieved in the ﬁ rst 
2 years remains over the long term and emphasises the 
safety of such strategy. The present analysis shows that 
very little catch-up occurs over time in the FFR-guided 
group. This is in agreement with the results of other 
studies deferring non-signiﬁ cant lesions as indicated 
by FFR.18,19
In the decision-making process with respect to 
revascularisation in multivessel disease, the SYNTAX 
score (not yet in existence at the time of writing the 
FAME protocol), has an important role. Therefore, a 
subanalysis according to SYNTAX score was done. No 
signiﬁ cant interaction was noted between the SYNTAX 
score and the beneﬁ t of treatment strategy.
A signiﬁ cant interaction between sex and treatment 
strategy was noted, favouring the male sex. In the male 
population, even after 5 years of follow-up, there was still 
a signiﬁ cant diﬀ erence favouring FFR-guided therapy. 
This beneﬁ t was not noted in the female population. This 
sex diﬀ erence was not present at the 2-year follow-up.19
Our 5-year follow-up analysis had limitations. First, 
this study was designed and powered for 1-year follow-up 
only. This 5-year follow-up was underpowered. Second, a 
noteworthy percentage of patients was lost to follow-up. 
A sensitivity analysis showed that the primary endpoint 
results were not signiﬁ cantly aﬀ ected by this loss to 
follow-up, which was balanced between the two groups. 
Third, we do not have data for whether events between 
2 years and 5 years were related to the index stenoses. 
Yet, events during the ﬁ rst 2 years in the FFR-guided 
group were mainly related to stent failure or new 
stenoses rather than to deferred lesions.10 Fourth, 
compliance to medical therapy and the presence or 
absence of anginal symptoms was unknown. Last, the 
drug-eluting stents used in the FAME study were ﬁ rst 
generation. These stents have now been shown to be 
inferior to second-generation drug-eluting stents, which 
have lower rates of stent thrombosis, target lesion 
revascularisation, and, in some cases, death and 
myocardial infarction.20–22
Our results conﬁ rm the long-term appropriateness and 
safety of FFR-guided PCI in patients with multivessel 
disease. Thus, FFR guidance of multivessel PCI should 
be the standard of care in most patients.
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